Adaptation of TeamBest FDG Technology Applied to Novel Prostate Cancer Specific Tracers

TeamBest FDG 技术应用于新型前列腺癌特异性示踪剂

• 批准号: 560741-2020
• 负责人: Marquardt, Drew
• 金额: $ 2.19万
• 依托单位: University of Windsor
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=707187
• 关键词: Adaptation; TeamBest; FDG; Technology; Applied

The usefulness of positron emission tomography (PET) imaging is best demonstrated by current data suggesting that in as many as one-third to one-half of cancer cases, physicians who do not have access to PET may be choosing the wrong management or treatment strategy for their patients. PET imaging relies on radiopharmaceuticals label with a radioactive element that decays through positron emmission. By far the most common radioisotope used for PET imagine is fluorine-18. The isotope fluorine-18 decays rapidly, with a half-life of 110 minutes. Such a short half-life makes shipping the radiotracers long distances expensive and often impractical. Thus synthesis of the radiopharmaceutical is ideally performed at the source of of fluorine 18. Although 96% of PET scans are perfomed with fluorodeoxyglucose (FDG), this particular radiotracer is non-specific and not ideal when monitior specific types of cancers. A up-and-coming PET approach is the use of Prostate specific membrane antigen imaging (PSMA). PSMA PET is very sensitive for detecting prostate cancer and is currently used in patients with new diagnosis of high-risk prostate cancer and those with biochemical recurrence. Thus, a reliable and expedient synthesis method of PSMA related PET agents is of high interest to the medical industry.

目前的数据表明，在多达三分之一到一半的癌症病例中，没有使用PET的医生可能会为患者选择错误的管理或治疗策略，这最好地证明了正电子发射断层扫描（PET）成像的有用性。